March 19, 2026 – Clear Lake, USA – Clariant, a global leader in specialty chemicals, has announced the expansion of its Clear Lake production facility with the addition of a new cGMP-compliant pharmaceutical-grade polyethylene glycol (PEG) excipient production line. This strategic capacity upgrade will drastically improve excipient supply volume and supply chain reliability for North American pharmaceutical customers, while extending market reach and responsive service to Latin America as part of the company’s pharma-focused growth roadmap.

The phased expansion project is tailored to address the global pharmaceutical industry’s top priorities: supply chain security, production continuity, and rapid response capabilities. It also reinforces Clariant’s long-term strategic commitment to the U.S. pharmaceutical market and regional healthcare manufacturing ecosystems, solidifying its position as a trusted partner for regulated drug production.

As Clariant’s first U.S.-based dedicated manufacturing site for pharmaceutical-grade PEG excipients, the Clear Lake facility represents a major milestone in the company’s global healthcare strategy. By establishing localized, regional production capacity, Clariant is building a resilient, agile supply chain infrastructure for North American and Latin American drug developers, contract manufacturing organizations (CDMOs), and pharmaceutical manufacturers, eliminating cross-border supply delays and enhancing inventory stability.

The upgraded Clear Lake plant adheres to the strictest global quality, safety, and regulatory standards for pharmaceutical excipients. Full excipient GMP compliance aligns all manufacturing processes with international pharmaceutical excipient guidelines, delivering comprehensive regulatory documentation, end-to-end traceability, and consistent quality assurance required for commercial and clinical drug production. Clariant’s pharmaceutical-grade PEG is registered in major pharmacopeias, boasts exceptionally low toxicity, and serves a broad spectrum of pharmaceutical applications across North America, Latin America, and global markets.